The Elijah E. Cummings Lower Drug Costs Now Act: How It Would Work, How It Would Affect Prices, and What the Challenges Are April 9, 2020 | Issue Briefs Featured Perverse Incentives: Why Brand-Name Drugs Can Cost Less Than Generics for Medicare BeneficiariesJuly 1, 2019 | Journal Article Reducing Wasteful Spending in Employers’ Pharmacy Benefit PlansAugust 30, 2019 | Issue Briefs Will Medicare Prescription Drug Reform Legislation Make Insulin More Affordable?April 2, 2020 | Journal Article Pharmacy Benefit Managers: Practices, Controversies, and What Lies AheadMarch 26, 2019 | Issue Briefs Prescription drugs accounted for 17 percent of total U.S. health care spending — or about $457 billion — in 2015. And that share is expected to rise over the next decade as drug costs outpace those of all other health care services. Policymakers need unbiased information and insight into what drives pharmaceutical prices and spending so they can develop feasible, effective policy solutions. Leave this field blank Our Experts Lovisa GustafssonVice President, Controlling Health Care Costs Media Mention read on: CNBCJanuary 14, 2019 Here's why many prescription drugs in the US cost so much—and it's not innovation or improvement FDA Actions on Drug Pricing A Timeline Explore Timeline The Latest in Prescription Drugs Narrow by: Author Anderson, ChloeAnderson, GerardAnderson, Kelly E.Baumgartner, Jesse C.Beutel, SophieBishop, ShawnBlumenthal, DavidBrooks-LaSure, ChiquitaCall, AdrienneColeman, AkeiisaCollins, Sara R.Conti, RenaCorr, BillDavis, KarenDoty, Michelle M.Duong, SophiaDusetzina, Stacie B.Ex, PatriciaFowler, ElizabethFrank, Richard G.Fry, CarrieGabel, Jon R.Ginsburg, Paul B.Glied, Sherry A.Green, Matthew Gunja, Munira Z.Gustafsson, LovisaGuyer, JocelynHorvath, JaneJha, Ashish K.Jost, Timothy S.Kang, So YeonKenyatta, KahaariKeohane, Laura M.Kesselheim, Aaron S.LaRosa, JoshLieberman, Steven M.Llamas, AlyssaMann, CindyMartin, KristiMcDonald, RuthMorgan, StevenMoulds, DonaldNuzum, RachelOran, RebeccaOsborn, RobinPanteli, DimitraPapanicolas, IreneParasrampuria, SonalPatel, KavitaPaxton, IsabelRamsay, ChristinaRiley, TrishRobinson, James C.Rodwin, Marc A.Rother, JohnSarnak, Dana O.Schneider, Eric C.Schoen, CathySeeley, ElizabethSeervai, ShanoorSen, Aditi P.Shah, ArnavSharp, JeremySquires, DavidStromberg, SamVela, LaurenWaxman, HenryWhitmore, HeidiWillink, AmberWoskie, Liana R.Wynne, BillyZhu, Benjamin Date Last 7 daysLast 30 daysLast 6 monthsPast yearOver a year agoOver 2 years agoOver 3 years agoOver 4 years agoOver 5 years ago Type Fund ReportsTo The PointIssue BriefsExplainerInfographicJournal ArticlePodcastOther Publication View By: Card View Card View List View Apply Leave this field blank To the Point Three Key Health Issues Congress Could Consider in 2018 Budget Deal February 2, 2018 By David Blumenthal, Shanoor Seervai To the Point Bipartisan Bill Would Increase Competition Among Drug Manufacturers and Lower Drug Prices January 29, 2018 By Henry Waxman, Bill Corr, Kristi Martin Publication Older Americans Were Sicker and Faced More Financial Barriers to Health Care Than Counterparts in Other Countries November 15, 2017 By Robin Osborn, Michelle M. Doty, Donald Moulds, Dana O. Sarnak, Arnav Shah Publication Brand-Name Drugs and Generics: Balancing Innovation with Cost Control November 3, 2017 By Aaron S. Kesselheim Publication Payers’ Experiences with Confidential Pharmaceutical Price Discounts: A Survey of Public and Statutory Health Systems in North America, Europe, and Australasia October 31, 2017 By Steven Morgan To the Point To Combat the Opioid Epidemic, We Must Be Honest About All Its Causes October 26, 2017 By David Blumenthal, Shanoor Seervai To the Point A Path Toward Understanding and Lowering U.S. Prescription Drug Spending October 17, 2017 By Shawn Bishop, Donald Moulds Publication Why Are U.S. Prescription Drug Prices So High? October 17, 2017 Publication Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier? October 5, 2017 By Dana O. Sarnak, David Squires, Shawn Bishop Publication Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending? September 27, 2017 By Elizabeth Seeley, Aaron S. Kesselheim Publication Strategies That Delay Market Entry of Generic Drugs September 18, 2017 By Aaron S. Kesselheim Publication Determinants of Market Exclusivity for Prescription Drugs in the United States September 13, 2017 By Aaron S. Kesselheim Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Next page Next › Last page Last »
